Eli Lilly and Company (LLY) 의 후행 P/E는 41.3, 선행 P/E 26.8. 후행 이익수익률은 2.42%, 선행 이익수익률 3.73%. PEG 0.43 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $123.61.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 86/100 5/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 29.6 | 2.08 | 5.78 | 3.82 | 2.67% |
| 2017 | -435.3 | 4.04 | 7.66 | 4.45 | 2.47% |
| 2018 | 36.8 | -0.02 | 12.10 | 5.53 | 1.94% |
| 2019 | 15.1 | 0.09 | 48.27 | 5.64 | 1.91% |
| 2020 | 26.1 | -1.02 | 28.63 | 6.58 | 1.66% |
| 2021 | 47.2 | -4.92 | 29.34 | 9.30 | 1.17% |
| 2022 | 55.7 | 4.52 | 32.64 | 12.18 | 1.02% |
| 2023 | 100.0 | -8.88 | 48.67 | 15.36 | 0.78% |
| 2024 | 65.7 | 0.65 | 48.99 | 15.44 | 0.67% |
| 2025 | 46.8 | 0.49 | 36.37 | 14.81 | 0.56% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $2.58 | $21.22B | $2.74B | 12.9% |
| 2017 | $-0.19 | $19.97B | $-204.1M | -1% |
| 2018 | $3.13 | $21.49B | $3.23B | 15% |
| 2019 | $4.96 | $22.32B | $8.32B | 37.3% |
| 2020 | $6.79 | $24.54B | $6.19B | 25.2% |
| 2021 | $6.12 | $28.32B | $5.58B | 19.7% |
| 2022 | $6.90 | $28.54B | $6.24B | 21.9% |
| 2023 | $5.80 | $34.12B | $5.24B | 15.4% |
| 2024 | $11.71 | $45.04B | $10.59B | 23.5% |
| 2025 | $22.95 | $65.18B | $20.64B | 31.7% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $34.43 | $30.46 – $37.40 | $81.69B | $78.74B – $83.17B | 17 |
| 2027 | $42.02 | $36.45 – $45.04 | $94.82B | $85.3B – $102.57B | 17 |
| 2028 | $49.21 | $42.81 – $55.85 | $106.38B | $106.1B – $106.65B | 9 |
| 2029 | $55.40 | $51.15 – $60.39 | $117.17B | $110.27B – $125.29B | 3 |
| 2030 | $60.97 | $56.30 – $66.47 | $126.59B | $119.14B – $135.37B | 3 |
